Pharmacoeconomic study of antibiotic therapy for exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in Latin America

Show simple item record

dc.contributor.author Miravitlles, M.
dc.contributor.author Jardim, José Roberto [UNIFESP]
dc.contributor.author Zitto, T.
dc.contributor.author Rodrigues, J. E.
dc.contributor.author Lopez, H.
dc.date.accessioned 2016-01-24T12:34:08Z
dc.date.available 2016-01-24T12:34:08Z
dc.date.issued 2003-12-01
dc.identifier http://www.archbronconeumol.org/en/linkresolver/estudio-farmacoeconomico-del-tratamiento-antibiotico/S0300289603754532/
dc.identifier.citation Archivos de Bronconeumologia. Barcelona: Ediciones Doyma S/l, v. 39, n. 12, p. 549-553, 2003.
dc.identifier.issn 0300-2896
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/27489
dc.description.abstract Chronic obstructive pulmonary disease (COPD) and chronic bronchitis are highly prevalent diseases. Studies designed to analyze the economic impact of these diseases in Latin American countries have not previously been published. in the present study we analyzed the direct health care costs of treating patients with exacerbations of chronic bronchitis and COPD in Argentina, Brazil, Colombia, Ecuador, Mexico, Peru, and Venezuela, applying the real cost of drugs and medical acts in those 7 countries to the pattern of treatment and outcomes obtained from a study carried out in primary care settings in Spain. the mean direct health care cost ranged from US $98 in Colombia to $329 in Argentina. Most of the cost was related to failure of therapy, which accounted for 52% of the total cost of exacerbation, with the lowest rate in Colombia at 28.6% and the highest in Ecuador at 59.3% the cost of antibiotic therapy represented 19% of the total cost; the rest was owing to other drugs or medical visits.Exacerbations generate significant costs for health care systems. There are considerable variations related mainly to differences between systems. Antibiotic therapy represents a small part of the overall cost. the use of more effective antibiotics, if they can reduce failure rates, may be a cost-effective strategy. en
dc.format.extent 549-553
dc.language.iso spa
dc.publisher Ediciones Doyma S/l
dc.relation.ispartof Archivos de Bronconeumologia
dc.rights Acesso aberto
dc.subject chronic bronchitis en
dc.subject chronic obstructive pulmonary disease (COPD) exacerbations en
dc.subject antibiotics en
dc.subject costs en
dc.subject pharmacoeconomics en
dc.title Pharmacoeconomic study of antibiotic therapy for exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in Latin America en
dc.type Artigo
dc.contributor.institution Hosp Clin Barcelona
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.contributor.institution Univ Buenos Aires
dc.description.affiliation Hosp Clin Barcelona, Serv Pneumol, Inst clin Pneumol & Cirurgia Torac, IDIBAPS, E-08036 Barcelona, Spain
dc.description.affiliation Universidade Federal de São Paulo, Serv Neumol, São Paulo, Brazil
dc.description.affiliation Universidade Federal de São Paulo, Grp Farmacoecon, EPOC, São Paulo, Brazil
dc.description.affiliation Univ Buenos Aires, Fac Med, Ctr Infect, RA-1427 Buenos Aires, DF, Argentina
dc.description.affiliationUnifesp Universidade Federal de São Paulo, Serv Neumol, São Paulo, Brazil
dc.description.affiliationUnifesp Universidade Federal de São Paulo, Grp Farmacoecon, EPOC, São Paulo, Brazil
dc.identifier.doi 10.1157/13054360
dc.description.source Web of Science
dc.identifier.wos WOS:000187621700004



File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account